Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Under Development: CBD Pharmaceutical Chewing Gum

By Globe Newswire | May 2, 2017

AXIM Biotech moves forward with development of Medchew Rx pharmaceutical chewing gum.

NEW YORK, May 2, 2017 – AXIM® Biotechnologies, Inc., a company focused on cannabinoid research and development, today announced that the company’s product development partner Quay Pharmaceuticals Ltd. (Quay Pharma) has obtained the relevant licenses from the British Home Office to import and work with the controlled drugs that are required to continue the development of AXIM MedChew Rx® pharmaceutical chewing gum’s family of products.

MedChew Rx – formulated with 5 mg of cannabidiol (CBD) and 5 mg of tetrahydrocannabinol (THC) – is being developed as a pharmaceutical drug to treat pain and spasticity associated with multiple sclerosis (MS).

According to research firm GlobalData, the value of the MS treatment market is estimated to reach $20 billion by 2024, primarily driven by the continued development of new products and an increase in diagnosis rates across major markets including US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India.

To develop and produce MedChew Rx family of chewing gums, AXIM Biotech works with its partners to procure cannabis strains, extract and purify the strains into pharmaceutical-grade cannabinoids, develop and produce the cannabinoid-containing chewing gum products and afterwards undertake clinical trials. All processes are based on AXIM’s proprietary IPs. 

Specifically, AXIM Biotech procures cannabinoid strains from the Dutch Government’s Office of Medicinal Cannabis (OMC), which is produced by Bedrocan BV at the world’s only GMP-certified facility for pharmaceutical grade cannabis. AXIM Biotech has co developed patented extraction and purification methods for 99.9% purity pharmaceutical-grade cannabinoids with Syncom BV.

The multilayer pharmaceutical chewing gum is developed by Quay Pharma in Great Britain.

“It is a very exciting development process we have embarked on with Axim and we are delighted to be supporting them on their range of projects. The development of the Med Chew RX gum will be carefully formulated to ensure that the drugs are preferentially absorbed orally within a specific window of time to provide the best therapeutic outcome for the patients,” commented Maireadh Pedersen, Chief Executive Officer of Quay Pharma.

Xendo B.V. is handling regulatory affairs, and QPS is an international clinical research organization in charge of managing the entire project including the clinical strategy and trials.

“We are excited to move forward the development of MedChew Rx pharmaceutical chewing gum with our world-class research and product development partners,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “For now, we are focusing on the prototypes of MedChew chewing gums and ensuring our products comply with all FDA/EMA regulations. After achieving product stability, we will start an efficacy Phase 2A clinical trials at the Free University in Amsterdam, and subsequently move onto a Phase 3 clinical trials in Vrije Universiteit Amsterdam, the UK and USA. We anticipate to complete Phase 3 clinical trials in early 2018.”

About AXIM®

AXIM® Biotechnologies, Inc. focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical, and cosmetic products. The company’s flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis.

(Source: Globe Newswire)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE